<DOC>
	<DOCNO>NCT01231802</DOCNO>
	<brief_summary>The purpose study determine eniluracil/5-FU/leucovorin metastatic breast cancer ( MBC ) may efficacy tolerability advantage capecitabine monotherapy .</brief_summary>
	<brief_title>Study Eniluracil + 5-Fluorouracil ( 5-FU ) + Leucovorin Versus Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>Histologically cytologically confirm metastatic ( Stage IV ) adenocarcinoma breast Prior exposure anthracyclines either neoadjuvant/adjuvant setting , treatment metastatic disease Either evidence recurrence development metastatic disease least 12 month last dose taxane neoadjuvant/adjuvant therapy , evidence disease progression receive taxane metastatic disease ECOG Performance Status 0 1 Measurable disease accord RECIST 1.1 Criteria Adequate renal , hematologic , hepatic function Negative pregnancy test willing use effective contraception Willing avoid dose form ( iv , oral , topical ) 5 FU related derivative 8 week follow last dose eniluracil Willing closely monitor change coagulation parameter ( prothrombin time and/or international normalize ratio [ INR ] value ) receive concomitant warfarin Pregnant lactating female Prior treatment capecitabine More one prior chemotherapy regimen metastatic disease Prior radiation must include ≥ 30 % major bone marrowcontaining area ( pelvis , lumbar spine ) . If prior radiation &lt; 30 % , minimum interval 6 week must allow last radiation treatment administration either study arm . Currently receive anticancer therapy Residual ≥ Grade 2 clinically significant side effect ( exclude alopecia ) associate prior radiotherapy , chemotherapy , investigational treatment Unstable CNS metastasis . However , subject asymptomatic systemic steroid anticonvulsant least 3 month exclude . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , ulcerative colitis , recent history GI bleed perforation History malignancy , except subject diseasefree 5 year subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma Concurrent disease condition would make subject inappropriate study participation , serious medical disorder would interfere subject 's safety Known history clinical evidence leptomeningeal carcinomatosis Active uncontrolled infection Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent Known history uncontrolled symptomatic angina , arrhythmia congestive heart failure Concurrent treatment investigational agent Use investigational drug within 30 day 5 halflives , whichever longer , precede first dose study medication Taking phenytoin Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically related capecitabine , fluorouracil , leucovorin , excipients Known dihydropyrimidine dehydrogenase ( DPD ) deficiency</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>